0RKL.LSE Xvivo Perfusion AB

Healthcare Commercial Services & Supplies London Exchange
280.75 SEK
Close of Nov 3, 2026
162.40 314.00
Market cap
SEK 7.41B
P/E
837.6x
P/B
-
ROE
5.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 0RKL.LSE undervalued?

Graham number

The Graham number of Xvivo Perfusion AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Xvivo Perfusion AB fundamental analysis

No fundamental analysis for Xvivo Perfusion AB yet.

Xvivo Perfusion AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Xvivo Perfusion AB

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clin…

Full company profile